8-氯-2-氯甲基-6-三氟甲基-咪唑并[1,2-A]吡啶 | 24381-49-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 8-氯-2-氯甲基-6-三氟甲基-咪唑并[1,2-A]吡啶
• 中文别名: 乳清酸胆碱脂
• 英文名称: Choline orotate
• 英文别名: 2,4-dioxo-1H-pyrimidine-6-carboxylate;2-hydroxyethyl(trimethyl)azanium
• CAS: 24381-49-5
• 化学式: C10H17N3O5
• 分子量: 259.26
• InChiKey: IMAGLCGCHKGGLR-UHFFFAOYSA-M

物化性质

• 熔点：
  151-152 °C
• LogP：
  -0.928 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.89
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] NOVEL COMPOSITIONS AND PROCESSES FOR PREPARING 5-AMINO OR SUBSTITUTED AMINO 1,2,3-TRIAZOLES AND TRIAZOLE OROTATE FORMULATIONS<br/>[FR] NOUVELLES COMPOSITIONS ET PROCÉDÉS DE PRÉPARATION DE 5-AMINO OU AMINO SUBSTITUÉ 1,2,3-TRIAZOLES ET DE FORMULATIONS D'OROTATE DE TRIAZOLE
  申请人：TACTICAL THERAPEUTICS INC

  公开号：WO2011028288A1

  公开（公告）日：2011-03-10

  New polymorphs of 5-amino or substituted amino 1, 2, 3-triazole and substituted derivatives thereof, of orotates of the carboxyamidotriazoles, of formulations of the triazoles and orotic acid in the ratio of 1:1 to 1:4 (base:acid) and of safer processes of the preparation of the same are disclosed. The compounds are useful in the control and treatment of diseases including, but not limited to solid cancers, macular degeneration, retinopathy, chronic myeloid leukemia, AIDS and diseases which rely on aberrant signal transduction. The improved processes to prepare the orotate formulations use stable, efficient and safer starting azide intermediate materials in the synthesis of new polymorphs of carboxyamidotriazole.

  公开了5-氨基或取代氨基1,2,3-三唑及其取代衍生物的新多形态，以及羧基氨基三唑的甲酸乳酸盐、三唑和甲酸的配方，比例为1:1至1:4（碱：酸），以及更安全的制备过程。这些化合物在控制和治疗疾病方面具有用途，包括但不限于固体癌症、黄斑变性、视网膜病变、慢性骨髓性白血病、艾滋病以及依赖异常信号传导的疾病。改进的制备甲酸盐配方的过程使用稳定、高效和更安全的起始叠氮中间体材料合成羧基氨基三唑的新多形态。
• Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
  申请人：Karmali Rashida A.

  公开号：US20140200247A1

  公开（公告）日：2014-07-17

  New polymorphs of 5-amino or substituted amino 1,2,3-triazole and substituted derivatives thereof, of orotates of the carboxyamidotriazoles, of formulations of the triazoles and orotic acid in the ratio of 1:1 to 1:4 (base:acid) and of safer processes of the preparation of the same are disclosed. The compounds are useful in the control and treatment of diseases including, but not limited to solid cancers, macular degeneration, retinopathy, chronic myeloid leukemia, AIDS and diseases which rely on aberrant signal transduction. The improved processes to prepare the orotate formulations use stable, efficient and safer starting azide intermediate materials in the synthesis of new polymorphs of carboxyamidotriazole.

  揭示了5-氨基或取代氨基1,2,3-三唑及其取代衍生物的新多态形式，以及羧基氨基三唑的噻唑酸盐、三唑和嘌呤酸的配方（以1:1至1:4的比例（碱：酸）），以及制备这些化合物的更安全的过程。这些化合物在控制和治疗疾病方面有用，包括但不限于实体癌症、黄斑变性、视网膜病变、慢性髓性白血病、艾滋病以及依赖异常信号传导的疾病。用于制备噻唑酸盐配方的改进过程使用稳定、高效和更安全的起始偶氮中间体材料合成羧基氨基三唑的新多态体。
• Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
  申请人：Karmali Rashida A.

  公开号：US20110060142A1

  公开（公告）日：2011-03-10

  New polymorphs of 5-amino or substituted amino 1,2,3-triazole and substituted derivatives thereof, of orotates of the carboxyamidotriazoles, of formulations of the triazoles and orotic acid in the ratio of 1:1 to 1:4 (base:acid) and of safer processes of the preparation of the same are disclosed. The compounds are useful in the control and treatment of diseases including, but not limited to solid cancers, macular degeneration, retinopathy, chronic myeloid leukemia, AIDS and diseases which rely on aberrant signal transduction. The improved processes to prepare the orotate formulations use stable, efficient and safer starting azide intermediate materials in the synthesis of new polymorphs of carboxyamidotriazole.

  本文公布了5-氨基或取代氨基1,2,3-三唑及其取代衍生物的新型多态形式，以及羧酰氨基三唑的奥罗酸盐、三唑和奥罗酸的配方（比例为1：1至1：4（碱：酸））和更安全的制备方法。这些化合物可用于控制和治疗包括但不限于实体癌症、黄斑变性、视网膜病变、慢性髓性白血病、艾滋病和依赖异常信号传导的疾病。改进的奥罗酸盐制剂的制备过程使用稳定、高效和更安全的起始叠氮中间体材料合成羧酰氨基三唑的新型多态形式。
• Treatment for depression and depressive disorders
  申请人：Medlab IP Pty Ltd

  公开号：US11135181B2

  公开（公告）日：2021-10-05

  Provided herein are methods and compositions for use in the treatment of depression, anxiety or a depressive or anxiety-related disorder. Embodiments describe the administration of orotic acid or a salt thereof, or the administration of one or more probiotic microorganisms, or administration of a combination of orotic acid or a salt thereof and one or more probiotic microorganisms.

  本文提供了用于治疗抑郁、焦虑或抑郁或焦虑相关疾病的方法和组合物。本发明的实施方案描述了奥罗酸或其盐的施用，或一种或多种益生微生物的施用，或奥罗酸或其盐与一种或多种益生微生物的组合施用。
• Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040247686A1

  公开（公告）日：2004-12-09

  The present invention relates to new pharmaceutical compositions for the treatment of skin disease. The composition comprises an antihistaminic-effective amount of Epinastine or a pharmaceutically acceptable salt thereof as a pharmacologically active compound and at least one compound selected from the group consisting of one or more sulfur containing amino acid(s) or peptide(s) as biologically active donor of a —S— or —SH group, at least one vitamin of the B group, at least one vitamin having antioxidant properties and an antiphlogistic-effective amount of an antiphlogistic compound. The compositions also may comprise pharmaceutically acceptable additives.

  本发明涉及治疗皮肤病的新药物组合物。该组合物包含抗组胺有效量的依匹斯汀或其药学上可接受的盐作为药理活性化合物，以及至少一种选自以下组成的化合物：一种或多种含硫氨基酸或肽作为-S-或-SH基团的生物活性供体、至少一种B族维生素、至少一种具有抗氧化特性的维生素和抗组胺有效量的抗组胺化合物。组合物还可包含药学上可接受的添加剂。